8K3C

Nipah virus Attachment glycoprotein with 41-6 antibody fragment

8K3C の概要

• エントリーDOI: 10.2210/pdb8k3c/pdb
• EMDBエントリー: 36849
• 分子名称: Light chain of 41-6 Fab fragment, Heavy chain of 41-6 Fab fragments, Glycoprotein G (3 entities in total)
• 機能のキーワード: nipah virus, attachment glycoprotein, tetramer complex, neutralizing antibody, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 154038.86

構造登録者

Sun, M.M. (登録日: 2023-07-15, 公開日: 2024-05-01, 最終更新日: 2024-11-13)

主引用文献

Chen, L.,Sun, M.,Zhang, H.,Zhang, X.,Yao, Y.,Li, M.,Li, K.,Fan, P.,Zhang, H.,Qin, Y.,Zhang, Z.,Li, E.,Chen, Z.,Guan, W.,Li, S.,Yu, C.,Zhang, K.,Gong, R.,Chiu, S.
Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains.
Nat Commun, 15:2987-2987, 2024

PubMed Abstract: Nipah virus (NiV) is a World Health Organization priority pathogen and there are currently no approved drugs for clinical immunotherapy. Through the use of a naïve human phage-displayed Fab library, two neutralizing antibodies (NiV41 and NiV42) targeting the NiV receptor binding protein (RBP) were identified. Following affinity maturation, antibodies derived from NiV41 display cross-reactivity against both NiV and Hendra virus (HeV), whereas the antibody based on NiV42 is only specific to NiV. Results of immunogenetic analysis reveal a correlation between the maturation of antibodies and their antiviral activity. In vivo testing of NiV41 and its mature form (41-6) show protective efficacy against a lethal NiV challenge in hamsters. Furthermore, a 2.88 Å Cryo-EM structure of the tetrameric RBP and antibody complex demonstrates that 41-6 blocks the receptor binding interface. These findings can be beneficial for the development of antiviral drugs and the design of vaccines with broad spectrum against henipaviruses.

PubMed: 38582870
DOI: 10.1038/s41467-024-47213-8

実験手法

ELECTRON MICROSCOPY (2.88 Å)